Caisson, CordenPharma in Mfg. pact.
Caisson Biotech, a provider of half-life extension and drug delivery, has established a global manufacturing partnership with CordenPharma, a full-service contract development and manufacturing organization (CDMO) manufacturing APIs and drug products through a network of cGMP facilities across Europe and the U.S.
Caisson has demonstrated successful technology transfer and cGMP scale-up with its pharmaceutical partners using its heparosan-based half-life extension and drug delivery platform, HEPtune, and will establish similar capabilities with CordenPharma in order to supply licensing partners with HEPtune drug conjugate material. As a manufacturer of the HEPtune technology, CordenPharma will provide process development and manufacture of complex carbohydrates, including carbohydrate-based polymers and glyco-conjugates, which are an integral component of its peptides, lipids and carbohydrates technology platform offering.
"We are excited to announce a manufacturing relationship with CordenPharma," said Breca Tracy, vice president and managing director, Caisson. "CordenPharma's experience manufacturing carbohydrates and polyethylene glycol drug conjugates makes CordenPharma an ideal scale-up manufacturing partner and will accelerate our capabilities to fulfill requests for larger quantities of quality material for preclinical and clinical studies."
Mimoun Ayoub, director, global peptides, lipids, carbohydrates and injectables platforms, CordenPharma, said, "We are delighted that Caisson Biotech has selected CordenPharma to serve as a manufacturer and supplier of HEPtune-related materials. This potentially disruptive technology is a natural fit for CordenPharma's peptides, lipids and carbohydrates platform, and we look forward to supporting Caisson's partners as they develop and commercialize life-saving therapeutics."